NCT00657605View on ClinicalTrials.gov

Effects of Human Leptin Replacement

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

May 4, 2010

Study Completion Date

May 4, 2010

Conditions
ObesityMetabolic SyndromeDiabetes
Interventions
DRUG

Recombinant methionyl human leptin

Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.

Trial Locations (1)

33136

University of Miami Miller School of Medicine, Center on Pharmacogenomics, Miami

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Miami

OTHER

NCT00657605 - Effects of Human Leptin Replacement | Biotech Hunter | Biotech Hunter